公开(公告)号：US20170044132A1

公开(公告)日：2017-02-16

申请号：US15304623

申请日：2015-04-16

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takaharu HIRAYAMA ,  Jun FUJIMOTO ,  Douglas Robert CARY ,  Masanori OKANIWA ,  Yasuhiro HIRATA

IPC: C07D401/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D401/14 ,  C07D487/08 ,  C07D491/08 ,  C07D405/14 ,  C07D487/04 ,  C07D491/107 ,  C07D417/04 ,  C07D409/14 ,  C07D498/08

CPC classification number: C07D401/04 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4704 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/553 ,  C07D213/64 ,  C07D401/14 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/08 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.

Abstract translation: （在该式中，符号如说明书中所定义）或其盐。

公开(公告)号：US20240209017A1

公开(公告)日：2024-06-27

申请号：US18052083

申请日：2022-11-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Stepan VYSKOCIL ,  Jeffrey CIAVARRI ,  Courtney CULLIS ,  Dylan Bradley ENGLAND ,  Alexandra E. GOULD ,  Paul GREENSPAN ,  Yongbo HU ,  Steven LANGSTON ,  Gang LI ,  Hirotake MIZUTANI ,  Masanori OKANIWA

IPC: C07H19/207

CPC classification number: C07H19/207

Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases.
The present disclosure relates to a compound represented by the Formula (I):






wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190359587A1

公开(公告)日：2019-11-28

申请号：US16332993

申请日：2017-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takaharu HIRAYAMA ,  Yasuhiro HIRATA ,  Yusuke TOMINARI ,  Naoki IWAMURA ,  Yusuke SASAKI ,  Moriteru ASANO ,  Terufumi TAKAGI ,  Masanori OKANIWA ,  Masato YOSHIDA ,  Shinichi IMAMURA

IPC: C07D401/04 ,  A61P35/00 ,  C07D409/14 ,  C07D401/14 ,  C07D417/14 ,  C07D407/14

Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20210171565A1

公开(公告)日：2021-06-10

申请号：US16762710

申请日：2018-11-09

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Stepan VYSKOCIL ,  Jeffrey CIAVARRI ,  Courtney CULLIS ,  Dylan Bradley ENGLAND ,  Alexandra E. GOULD ,  Paul GREENSPAN ,  Yongbo HU ,  Steven LANGSTON ,  Gang LI ,  Hirotake MIZUTANI ,  Masanori OKANIWA

IPC: C07H19/207

Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190241566A1

公开(公告)日：2019-08-08

申请号：US16333296

申请日：2017-09-14

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takaharu HIRAYAMA ,  Yasuhiro HIRATA ,  Yusuke TOMINARI ,  Naoki IWAMURA ,  Yusuke SASAKI ,  Moriteru ASANO ,  Terufumi TAKAGI ,  Masanori OKANIWA ,  Masato YOSHIDA ,  Takashi ICHIKAWA ,  Shinichi IMAMURA

IPC: C07D473/28 ,  C07D473/40 ,  C07D519/00 ,  C07D471/04 ,  C07D417/14 ,  C07D413/14 ,  C07D401/14 ,  C07D409/14 ,  C07D405/14 ,  C07D401/04 ,  A61P35/00

Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.